Key Highlights:
- Nine stocks fell between 14.86% and 19.60% on Friday, October 23, 2026, led by LKQ.
- Only LKQ, Atlantic American and Huachen AI Parking Management Technology tied the session to a company disclosure, with Huachen trading for the first time after a reverse split.
- Four decliners, Atlantic American, Huachen, Top Wealth Group and Quhuo, face Nasdaq compliance or delisting issues.
- Quhuo's 32,000-for-1 consolidation is about 3.6 times Top Wealth Group's 9,000-fold combined consolidation (calculated).
- Six of the nine, including Tango Therapeutics and Phathom Pharmaceuticals, have not announced a catalyst for the drop.
Which Stocks Fell the Most on October 23, 2026?
Nine stocks fell by more than 14% on Friday, October 23, 2026, and the causes ranged from withdrawn guidance to share-structure changes. LKQ (NASDAQ:LKQ) dropped 19.60% to $18.07 after preliminary results and a chief executive exit, and Algorhythm Holdings (NASDAQ:RIME) fell 18.24% to $0.0995. Huachen AI Parking Management Technology (NASDAQ:HCAI) lost 16.77% to $2.68 in its first post-split session, Atlantic American (NASDAQ:AAME) 15.79% to $1.33 and Top Wealth Group (NASDAQ:TWG) 15.68% to $0.0398. Phathom Pharmaceuticals (NASDAQ:PHAT) declined 15.55% to $5.92, Tango Therapeutics (NASDAQ:TNGX) 15.11% to $23.71, Quhuo (NASDAQ:QH) 14.93% to $3.02 and Roma Green Finance (NASDAQ:ROMA) 14.86% to $5.81.
LKQ: Why Did Guidance Disappear Alongside the Chief Executive?
The auto parts distributor issued preliminary third-quarter results on October 23, ahead of its October 29 report. Adjusted EPS of $0.47 to $0.53 compared with $0.84, and revenue of $3.32 billion was about 5.1% lower (calculated). European organic revenue fell 9.8%, which the company tied to an ERP rollout in Germany. It withdrew 2026 guidance, the chief executive left, and a new one starts December 15. The implied prior close is near $22.48, a drop of about $4.41 per share (calculated).
Algorhythm Holdings: Is Dilution the Pressure Behind the Slide Under $0.10?
The company has not announced a catalyst. Volume of about 63.87 million shares compared with an average of 8.06 million. In September it bought Azure Energy assets for about $23 million in stock, and it ended a share-settlement arrangement with a lender. A strategic review of its SemiCab unit, announced August 25, has no decision. The 52-week range runs from $0.085 to $4.58, so the price is about 97.8% below the high (calculated).
Huachen AI Parking Management Technology: What Does a Second Reverse Split Do to Its Offering Price Gap?
The 1-for-20 reverse split took effect at the open, and the Chinese smart parking company has not announced another catalyst. Class A shares fell from 10,379,942 to about 518,997. The September 15 offering priced at $1.00, or $20.00 after the split, so the stock trades about 86.6% below it (calculated). A 1-for-30 split in April means the two combined equal a factor of 600 (calculated). No next event is dated.
Atlantic American: How Many Reports Stand Between the Insurer and Compliance?
Nasdaq issued a Staff Delisting Determination on October 16 after an October 12 deadline passed. The 2025 annual report is filed, but the first and second-quarter 2026 reports are not. A hearing request was due October 23, with a 15-day automatic stay and a panel hearing expected 30 to 45 days later. Its last quarterly report showed revenue of $53.8 million, and the shares equal about 0.26 times September 2025 book value (calculated).
Top Wealth Group: Does Growth in Caviar Sales Offset a Cash Balance Under $300,000?
The company has not announced a catalyst. A 1-for-100 consolidation takes effect October 26, after a correction to an earlier October 22 date, and the post-split equivalent price is $3.98 (calculated). First-half revenue rose about 48% to $6.15 million, but cash was $295,256 on June 30. Nasdaq set a March 31, 2027 deadline for bid price compliance, and the company is moving its headquarters to France.
Phathom Pharmaceuticals: Can Fast Sales Growth Explain a Drop With No Announcement?
The company has not announced a catalyst. Second-quarter VOQUEZNA net revenue rose 88% to $74.3 million, and the net loss narrowed to $17.6 million. In July it cut 2026 revenue guidance to $310 million to $325 million from $320 million to $345 million. Cash was $182.5 million against liabilities of $671.3 million. Third-quarter results and a webcast are set for October 29, 2026, and Phase 2 topline data are expected in the fourth quarter.
Tango Therapeutics: Did Congress Week Positioning Push the Shares Down?
The company has not announced a separate catalyst. The session coincided with the opening of the ESMO Congress, where vopimetostat combination data in pancreatic cancer are due. Earlier results showed a 92% response rate and 90% six-month progression-free survival. Cash was $1.0 billion on June 30, and the second-quarter net loss was $55.3 million. The price is about 14.3% below the August 10 close (calculated). The congress runs through October 27.
Quhuo: What Remains of the Nasdaq Conditions After the 32,000-for-1 Consolidation?
The company has not announced a catalyst. Its depositary receipt program ended July 17, when Class A shares began trading directly, and the prior close was about $3.55 (calculated). A Nasdaq panel allowed the shares to stay on the exchange, and the company accepted conditions on May 27, including a one-year pause on external financing. Fiscal 2025 revenue was $361.2 million with a gross margin of 0.5% and a net loss of $21.4 million.
Roma Green Finance: How Does a Revenue Drop Fit a Stock Still Far Above Its Low?
The company has not announced a catalyst. Fiscal 2026 revenue fell 22.19% to HK$9.49 million, and the net loss was HK$27.32 million. The 52-week range is $1.16 to $11.77, putting the price about 50.6% below the high (calculated). A $100 million repurchase program dates from March 30, 2026, and the company has also announced non-binding letters of intent for stakes in two AI infrastructure businesses. No next event is announced.
Double-Digit Decliners Compared: How Far Are the Shares From Their Reference Points?
Each decliner can be measured against a sourced reference price. Huachen AI Parking Management Technology sits about 86.6% below its split-adjusted September offering price (calculated), Algorhythm Holdings about 97.8% below its 52-week high, and Roma Green Finance about 50.6% below its high (calculated). Quhuo is about 29.8% below its early August price near $4.30, and Tango Therapeutics about 14.3% below its August 10 close (calculated).
Share-structure resets differ in scale. Quhuo's 32,000-for-1 consolidation is about 3.6 times Top Wealth Group's combined 9,000-fold factor, which is itself 15 times Huachen's combined factor of 600 (calculated).
The best and worst sessions were 4.74 percentage points apart (calculated), from LKQ at 19.60% to Roma Green Finance at 14.86%. LKQ's decline was about 1.32 times Roma Green Finance's (calculated).
What to Watch Next: Which Dated Events Could Move the Decliners?
LKQ and Phathom Pharmaceuticals both report on October 29, 2026, while Tango Therapeutics' congress presentations run through October 27. Top Wealth Group's consolidation takes effect on October 26, and Atlantic American's panel hearing is expected roughly 30 to 45 days after its October 23 request. Top Wealth Group faces a March 31, 2027 compliance deadline, and LKQ's new chief executive starts December 15. Algorhythm Holdings, Huachen, Quhuo and Roma Green Finance have no announced dates.
LKQ fell 19.60% to $18.07 after preliminary third-quarter results, withdrawn 2026 guidance and a chief executive exit.
Atlantic American, Huachen AI Parking Management Technology, Top Wealth Group and Quhuo face delisting or minimum bid price matters.
Both are scheduled to report third-quarter results on October 29, 2026.






Please wait processing your request...